How to buy Enochian Biosciences stock

Enochian Biosciences, Inc is a biotechnology business based in the US. Enochian Biosciences shares (ENOB) are listed on the NASDAQ and all prices are listed in US Dollars. Enochian Biosciences employs 10 staff and has a market cap (total outstanding shares value) of 0.00.

Enochian Biosciences share price

Use our graph to track the performance of ENOB stocks over time.

Enochian Biosciences shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$2.60 - $4.90
50-day moving average	$3.49
200-day moving average	$3.38
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.48

Buy Enochian Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Enochian Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Enochian Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Enochian Biosciences financials

Gross profit TTM	$0
Return on assets TTM	-4.57%
Return on equity TTM	-6.57%
Profit margin	0%
Book value	$3.46
Market capitalisation	$159 million

TTM: trailing 12 months

Shorting Enochian Biosciences shares

There are currently 1.4 million Enochian Biosciences shares held short by investors – that's known as Enochian Biosciences's "short interest". This figure is 28.9% up from 1.1 million last month.

There are a few different ways that this level of interest in shorting Enochian Biosciences shares can be evaluated.

Enochian Biosciences's "short interest ratio" (SIR)

Enochian Biosciences's "short interest ratio" (SIR) is the quantity of Enochian Biosciences shares currently shorted divided by the average quantity of Enochian Biosciences shares traded daily (recently around 491538.5665529). Enochian Biosciences's SIR currently stands at 2.93. In other words for every 100,000 Enochian Biosciences shares traded daily on the market, roughly 2930 shares are currently held short.

However Enochian Biosciences's short interest can also be evaluated against the total number of Enochian Biosciences shares, or, against the total number of tradable Enochian Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Enochian Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Enochian Biosciences shares in existence, roughly 30 shares are currently held short) or 0.197% of the tradable shares (for every 100,000 tradable Enochian Biosciences shares, roughly 197 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Enochian Biosciences.

Find out more about how you can short Enochian Biosciences stock.

Enochian Biosciences share dividends

We're not expecting Enochian Biosciences to pay a dividend over the next 12 months.

Enochian Biosciences share price volatility

Over the last 12 months, Enochian Biosciences's shares have ranged in value from as little as $2.6 up to $4.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enochian Biosciences's is 0.3197. This would suggest that Enochian Biosciences's shares are less volatile than average (for this exchange).

Enochian Biosciences overview

Enochian Biosciences, Inc. , a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute.

Frequently asked questions

• What percentage of Enochian Biosciences is owned by insiders or institutions?

  Currently 68.674% of Enochian Biosciences shares are held by insiders and 5.289% by institutions.

• How many people work for Enochian Biosciences?

  Latest data suggests 10 work at Enochian Biosciences.

• When does the fiscal year end for Enochian Biosciences?

  Enochian Biosciences's fiscal year ends in June.

• Where is Enochian Biosciences based?

  Enochian Biosciences's address is: Century City Medical Plaza, Los Angeles, CA, United States, 90067-2012

• What is Enochian Biosciences's ISIN number?

  Enochian Biosciences's international securities identification number is: US29350E1047

• What is Enochian Biosciences's CUSIP number?

  Enochian Biosciences's Committee on Uniform Securities Identification Procedures number is: 236078101